Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 10/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004255 | 0.86 | CYP1A2 (0.39) | MEN1KMT2AESR1ATMESR2 | |
| SCHEMBL4003706 | 0.85 | TTK (0.37) | MEN1KMT2AESR1ATMESR2 | |
| SCHEMBL4007104 | 0.85 | F2 (0.38) | MEN1KMT2AESR1ATMESR2 | |
| SCHEMBL4007930 | 0.84 | TTK (0.56) | TTKMAPK8CSNK2A1NTRK1NPC1 | |
| SCHEMBL4008425 | 0.83 | PRKAG1 (0.40) | TTKF2MAPK8CSNK2A1NTRK1 | |
| SCHEMBL4007876 | 0.82 | LRRK2 (0.37) | MEN1KMT2AESR1ATMESR2 | |
| SCHEMBL4008356 | 0.82 | YTHDC1 (0.53) | CSNK2A1NTRK1 | |
| SCHEMBL4013510 | 0.80 | HSD11B1 (0.41) | MEN1KMT2AESR1ESR2CSNK2A1 | |
| SCHEMBL4013630 | 0.79 | CDK7 (0.53) | MAPK8CSNK2A1NTRK1 | |
| SCHEMBL4009831 | 0.79 | CSNK2A1 (0.54) | CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MEN1 2247/4885KMT2A 1089/4885ESR1 3077/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | MEN1 2443/4885KMT2A 1222/4885ESR1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.